Contera Pharma will receive an upfront payment and full research funding for each target under investigation
The SELECT-SWITCH study, first head-to-head Phase 3b/4 trial, compared switching to Rinvoq versus switching to another TNF inhibitor
Approval broadens indication for Tezspire to a second disease characterized by epithelial-driven inflammation
Zaltenibart offers best-in-class potential across multiple rare blood and kidney disorders, enhancing Novo Nordisk’s rare disease portfolio
Lutavit A/D3 1000/200 NXT provides a combination of vitamin A and vitamin D3 in one formulation
This new suite of products demonstrates Nouryon’s leadership in cleaning ingredient solutions
These findings follow positive Phase 3 results presented earlier this year
Anil Gupta has been appointed as the Senior Vice President, and Sanjay Singhania has taken charge as the Vice President of PHDCCI
The new plant will manufacture high-quality Type I borosilicate glass tubing
Updated indication expands treatment options for patients with ulcerative colitis and Crohn’s disease when tumor necrosis factor (TNF) blockers are clinically inadvisable
Subscribe To Our Newsletter & Stay Updated
